Novaliq’s NovaTears, Omega-3 combo approved in Europe for evaporative dry eye disease

Privately-held pharma company Novaliq GmbH said this week that its NovaTears+Omega-3 combo therapy for patients with evaporative dry disease was registered in Europe.

The treatment uses Novaliq’s water-free EyeSol drug delivery tech and is available in a multi-dose bottle. The company touted its product as the first eye drop to contain high concentrations of Omega-3 ethyl ester.

Get the full story at our sister site, Drug Delivery Business News.

The post Novaliq’s NovaTears, Omega-3 combo approved in Europe for evaporative dry eye disease appeared first on MassDevice.

from MassDevice http://ift.tt/2AonwSs